Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 stud
Date
Journal Title
Journal ISSN
Volume Title
Publisher
PUBLIC LIBRARY SCIENCE
Abstract
Description
Keywords
Citation
WOS